Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

New directions in bicyclopentane research

Objetivo

The pharmaceutical industry is increasingly seeking new tactics for the structural modification of drug candidates to avoid metabolic susceptibility, or to improve pharmacokinetic properties. Analogues called 'bioisosteres', which mimic the dimensions and substituent directionality of problematic structural motifs, but which are not themselves subject to the same pharmacological issues, offer one solution. Often based on scaffolds not found in ‘typical’ drug candidates, bioisosteres can additionally occupy new areas of intellectual property space. Within this growing field, rigid polycycles such as bicyclo[1.1.1]pentane (BCP) are receiving significant attention as arene bioisosteres, as they exhibit similar ring diameters and substituent positioning, and also improve many pharmacokinetic properties relative to the parent arene. Despite the attractive nature of these motifs and current interest, the lack of general routes to complex BCP ring systems means this template is not yet fully accessible to industry. The invention of mild methods for [1.1.1.0]tricyclopentane (TCP) ring opening and functionalization could revolutionize use of BCPs in the pharmaceutical sector.
One method not explored to date is an atom transfer radical addition reaction (ATRA) strategy. Using aryl or alkyl halides, ATRA could deliver an abundance of previously inaccessible polysubstituted BCPs from generalized TCP, which would revolutionize this immature, cutting-edge area of organic and medicinal chemistry.
This research proposal seeks to: i) explore general and mild ATRA-based syntheses of BCP derivatives, including ring-expanded (hetero)bioisosteres; ii) functionalize BCP products using a range of contemporary processes, including C–H or C–X activation; and iii) apply these methodologies to synthesize BCP drugs / natural product analogues, and to test their biological activity via an industrial collaboration.

Ámbito científico (EuroSciVoc)

Programa(s)

Tema(s)

Régimen de financiación

MSCA-IF-EF-ST - Standard EF

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) H2020-MSCA-IF-2017

Ver todos los proyectos financiados en el marco de esta convocatoria

Coordinador

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Aportación neta de la UEn
€ 183 454,80
Dirección
WELLINGTON SQUARE UNIVERSITY OFFICES
OX1 2JD Oxford
Reino Unido
Región
South East (England) Berkshire, Buckinghamshire and Oxfordshire Oxfordshire
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
€ 183 454,80